Pre-Existing Vitamin D Deficiency Associated with Lower Overall Survival and Progression-Free Rates in Hodgkin Lymphoma
Authors/Creators
- 1. Associate Professor, Department of Radiotherapy, Darbhanga Medical College, Darbhanga, Bihar, India
- 2. Senior Resident, Department of Radiotherapy, Darbhanga Medical College, Darbhanga, Bihar, India
Description
Background: Vitamin D deficit is known as a changeable risk factor in many common cancers, but its impact on Hodgkin lymphoma (HL) is not well-studied. Methods: This study assessed pre-treatment vit. D levels in HL individuals who received prospective treatment. It included 35 individuals from the North Bihar Population. Results: Vitamin D levels < 30 nmol/L were observed in 49% of patients before therapy. Vitamin D deficiency increased relapse/refractory rates. Relapsed/refractory patients exhibited lower median baseline Vitamin D levels (21.4 nmol/L) than non-relapsed (35.5). The non-relapsed group had 41% Vitamin D insufficiency, while relapsed/refractory patients had 68%. The 10-year progression-free survival of vitamin D-deficient patients was 17.6% poorer with a hazard ratio of 2.13. Their 10-year survival rate was 11.1% lower and their hazard ratio was 1.82. These results were consistent across studies and treatments. Vitamin D status independently predicted prognosis, suggesting it may impact HL chemotherapeutic sensitivity. Conclusion: It is advised that future randomized clinical trials include vitamin D assessment and replacement in order to ascertain the function of vitamin D replacement treatment in HL, based on these medical and preclinical findings.
Abstract (English)
Background: Vitamin D deficit is known as a changeable risk factor in many common cancers, but its impact on Hodgkin lymphoma (HL) is not well-studied. Methods: This study assessed pre-treatment vit. D levels in HL individuals who received prospective treatment. It included 35 individuals from the North Bihar Population. Results: Vitamin D levels < 30 nmol/L were observed in 49% of patients before therapy. Vitamin D deficiency increased relapse/refractory rates. Relapsed/refractory patients exhibited lower median baseline Vitamin D levels (21.4 nmol/L) than non-relapsed (35.5). The non-relapsed group had 41% Vitamin D insufficiency, while relapsed/refractory patients had 68%. The 10-year progression-free survival of vitamin D-deficient patients was 17.6% poorer with a hazard ratio of 2.13. Their 10-year survival rate was 11.1% lower and their hazard ratio was 1.82. These results were consistent across studies and treatments. Vitamin D status independently predicted prognosis, suggesting it may impact HL chemotherapeutic sensitivity. Conclusion: It is advised that future randomized clinical trials include vitamin D assessment and replacement in order to ascertain the function of vitamin D replacement treatment in HL, based on these medical and preclinical findings.
Files
IJPCR,Vol15,Issue11,Article245.pdf
Files
(265.8 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:8c3715d547aad0cd805ce29bf82aa915
|
265.8 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-11-18
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/15/IJPCR,Vol15,Issue11,Article245.pdf
- Development Status
- Active
References
- 1. Institute of Medicine: Summary: Conclusions about vitamin D deficiency in the United States and Canada, in Ross AC, Taylor CL, Yaktin AL, et al (eds): Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC, National Academies Press, 2011;13-14. 2. Boscoe FP, Schymura MJ: Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993-2002. BMC Cancer. 2006; 6: 264. 3. Heath AK, Kim IY, Hodge AM, et al: Vitamin D status and mortality: A systematic review of observational studies. Int J Environ Res Public Health. 2019; 16:383. 4. Yu H-J, Kwon M-J, Woo H-Y, et al: Analysis of 25-hydroxyvitamin D status according to age, gender, and seasonal variation. J Clin Lab Anal. 2016; 30:905-911. 5. Wang W, Li G, He X, et al: Serum 25- hydroxyvitamin D levels and prognosis in hematological malignancies: A systematic review and meta-analysis. Cell Physiol Biochem. 2015; 35:1999-2005. 6. Borchmann S, Muller H, Engert A: Hodgkin lymphoma has a seasonal pattern of incidence and mortality that depends on latitude. Sci Rep. 2017; 7:14903. 7. Porojnicu AC, Robsahm TE, Ree AH, et al: Season of diagnosis is a prognostic factor in Hodgkin's lymphoma: A possible role of suninduced vitamin D. Br J Cancer. 2005; 93:571- 574. 8. Institute of Medicine Standing Committee on the Scientific Evaluation of Dietary Reference Intakes: Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington DC, National Academies Press, 1997. 9. Wei R, Christakos S: Mechanisms underlying the regulation of innate and adaptive immunity by vitamin D. Nutrients. 2015; 7:8251-8260. 10. Sasse S, Brockelmann PJ, Goergen H, et al: Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: Updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials. J Clin Oncol. 2017; 35:1999-2007. 11. Renne C, Benz AH, Hansmann ML: Vitamin D3 receptor is highly expressed in Hodgkin's lymphoma. BMC Cancer. 2012; 12:215.